Delivery Order SPE2DB22D3301-SPE2DB25FY0PH

Award Date 2/25/25
Potential Completion Date 2/26/25
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $25,827.78, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of the drug RUXIENCE 500 MG/50 ML VIAL 50ML. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,614.74, is a Firm Fixed Price Delivery Order for the supply of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a...
This federal contract award, valued at $10,028.84, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order (DO) against the company's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The award covers the procurement of 4565255148 - RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical...
This federal contract award, valued at $2,446.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product, to support military healthcare programs. The contract has an ultimate completion date of January 21, 2025 and is a Firm Fixed Price Delivery Order, with no set-aside designation indicated....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,789.36, is for the delivery of Ruxience 500 mg/50 ml vial, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of February 26, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,293.56 Delivery Order contract is for the supply of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,728.70 firm fixed price delivery order is for the supply of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product. The contract has an ultimate completion date of December 28, 2023 and was awarded on December 27, 2023. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,571.86, is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of January 14, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,174.08 firm fixed-price delivery order is for the supply of RUXIENCE 100 MG/10 ML VIAL 10ML, a pharmaceutical product. The contract has an ultimate completion date of December 12, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a major defense agency, to AmerisourceBergen Drug Corp, a prominent pharmaceutical distributor, for the delivery of 500 mg/50 ml vials of the drug RUXIENCE. The contract has a ceiling value of $31,324.15 and is a firm-fixed price delivery order that runs through September 6, 2024. This award is likely part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that...
  • SPE2DB22D3301
    Indefinite Delivery Contract
  • SPE2DB22D3301-SPE2DB25FY0PH
    Delivery Order

This federal contract award, valued at $11,475.79, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product, with a completion date of February 26, 2025.

The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains.

The contract award does not have a set-aside designation, indicating open competition.

Generated 5/27/25, 9:44 AM